Harrow (NASDAQ:HROW) Trading Down 4.9% – What’s Next?

Harrow, Inc. (NASDAQ:HROW) shares fell 4.9% during trading on Tuesday . The company traded as low as $39.51 and last traded at $39.79. 75,863 shares were traded during trading, a decline of 85% from the average session volume of 508,519 shares. The stock had previously closed at $41.86.

Analysts Set New Price Targets

Several analysts have weighed in on the company. B. Riley reissued a “buy” rating and issued a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Lake Street Capital raised their target price on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. Finally, Craig Hallum upped their price target on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 4th.

Harrow Price Performance

The business has a 50-day moving average of $47.56 and a 200 day moving average of $34.87. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Institutional Trading of Harrow

Several hedge funds and other institutional investors have recently bought and sold shares of HROW. First Turn Management LLC purchased a new position in shares of Harrow during the 3rd quarter worth $14,683,000. Private Capital Management LLC increased its stake in Harrow by 7.8% in the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after purchasing an additional 217,896 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Harrow during the third quarter worth about $8,572,000. Charles Schwab Investment Management Inc. boosted its stake in Harrow by 195.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after buying an additional 166,602 shares during the last quarter. Finally, Braidwell LP grew its holdings in Harrow by 47.9% in the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after buying an additional 142,450 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.